CG Oncology

CGON

Market cap $3.3B

Overview Fund Trends Analyst Outlook Journalist POV

43.27 USD

+0.80

1.88%

At close Updated Oct 31, 4:00 PM EDT

Pre-market

After hours

43.27

0.00

1 day

1.88%

5 days

-0.67%

1 month

7.42%

3 months

62.12%

6 months

60.62%

Year to date

49.36%

1 year

21.78%

5 years

16.41%

10 years

16.41%

About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Employees: 113

Healthcare Biotechnology